News Focus
News Focus
icon url

DewDiligence

11/28/06 3:44 PM

#2042 RE: DewDiligence #1991

Use of Recombinant Factor VIIa (NovoSeven) for
Treatment of Active Or Impending Bleeding in
Brain Injury: Broadening the Indications


http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&l...

>>
J Clin Anesth. 2006 Nov;18(7):545-51.

Yusim Y, Perel A, Berkenstadt H, Attia M, Knoller N, Sidi A.

Department of Anesthesiology, Sheba Medical Center, Tel-Hashomer 52621, Israel.

We report three patients with severe traumatic brain injury, both open and closed, who were treated with recombinant activated factor VII. This treatment was given in a desperate, last-ditch effort to save the life of patient 1, as a preventive or early treatment of a developing hematoma in patient 2, and as treatment of a threatening hematoma in patient 3. One of the three patients survived.

During the past few years we have broadened the indications for recombinant activated factor VII and started using it as a preventive measure rather than as a "last line of defense." However, the potential complications of disseminated intravascular coagulation and thrombotic events, as well as the cost-effectiveness in view of the available evidence-based medicine, should be considered.
<<
icon url

DewDiligence

11/28/06 4:05 PM

#2043 RE: DewDiligence #1991

Recombinant Factor VIIa in Massive Postpartum Hemorrhage

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&l...

>>
Int J Obstet Anesth. 2006 Nov 22.

Karalapillai D, Popham P.

Department of Anaesthesia, Royal Women's Hospital, Carlton, Victoria, Australia.

Massive postpartum haemorrhage is a major cause of maternal and fetal morbidity and mortality. Management mainstays include transfusion therapy, uterotonic agents and surgery. The "off label" use of recombinant activated factor VII appears to have an evolving role in the management of massive postpartum haemorrhage refractory to conventional treatments. The current literature is reviewed.
<<
icon url

DewDiligence

01/13/07 5:52 PM

#2438 RE: DewDiligence #1991

MAXY JPM webcast broaches ‘enhanced’ FVIIa market:

http://www.mapdigital.com/jpmorgan/healthcare07/ondemand.html?archives=windowsmedia#m

The portion of the webcast relevant to FVIIa is at 16:15-20:00. The graphic in #msg-15036896 is helpful to refer to.